29 Aug, 2023 09:50 AM
Treatment of the third clinical trial participant, required to complete the final dose escalation cohort in the CHM 1101 Phase 1A clinical trial, has been completed at City of&n...read more
15 Aug, 2023 08:35 AM
Sydney, Australia, 15 August 2023: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to announce positive in vitr...read more
31 Jul, 2023 02:41 PM
Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to provide a summary of its activities for the quarter ended 30...read more
23 Jun, 2023 02:40 PM
Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), the only ASX-listed clinical stage cell therapy company, announces the successful completion of its Securities P...read more
28 Apr, 2023 06:36 PM
Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to provide a summary of its activities for the quarter end...read more
28 Apr, 2023 10:35 AM
Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), the only ASX-listed clinical stage cell therapy company, is pleased to announce that the Indian Patent Offi...read more
03 Apr, 2023 02:15 PM
-- Acceptance of CHM 1101 abstract for presentation at premier oncology meeting, Annual Meeting of the American Society of Clinical Oncology (ASCO)
-- Abstract will highlight the clinical trial des...read more